hsp70 elisa kit  (R&D Systems)

Journal: Biomedicines

Article Title: Biomarkers in Adult-Type Diffuse Gliomas: Elevated Levels of Circulating Vesicular Heat Shock Protein 70 Serve as a Biomarker in Grade 4 Glioblastoma and Increase NK Cell Frequencies in Grade 3 Glioma.

doi: 10.3390/biomedicines11123235

Figure Lengend Snippet: Figure 3. Representative immunohistochemical staining of intracellular Hsp70 levels in tumor sections of grade 3 and grade 4 gliomas using cmHsp70.1 mAb. Scale bars, 100 µm and 200 µm.

Article Snippet: The concentration of free Hsp70 in the serum samples, as measured with the R&D Systems DuoSet® Total Hsp70 ELISA, was also significantly elevated in patients with GBM (** p < 0.01) compared to the healthy i dividuals (Figure 4B), with median Hsp70 levels of 3.5 ng/mL (GBM) nd 2.6 ng/mL (healthy), respectively.

Techniques: Immunohistochemical staining, Staining

Journal: Biomedicines

Article Title: Biomarkers in Adult-Type Diffuse Gliomas: Elevated Levels of Circulating Vesicular Heat Shock Protein 70 Serve as a Biomarker in Grade 4 Glioblastoma and Increase NK Cell Frequencies in Grade 3 Glioma.

doi: 10.3390/biomedicines11123235

Figure Lengend Snippet: Figure 4. (A) Free and vesicular Hsp70 (ng/mL) levels measured in the plasma of healthy donors (n = 118; Hsp70 median, 18.9 ng/mL) and patients with oligodendroglioma (n = 10; Hsp70 median, 14.8 ng/mL), astrocytoma (n = 13; Hsp70 median, 27.5 ng/mL), and GBM (n = 76; Hsp70 median, 45.4 ng/mL), as measured using the Hsp70-exo ELISA. (B) Free Hsp70 levels measured in the serum of healthy donors (n = 150; Hsp70 median, 2.6 ng/mL) and patients with oligodendroglioma (n = 7; Hsp70 median, 2.4 ng/mL), astrocytoma (n = 5, Hsp70 median, 3.4 ng/mL), and GBM (n = 51; Hsp70 median, 3.5 ng/mL) using the DuoSet® IC Human/Mouse/Rat Total Hsp70 ELISA. Statistically significant differences ** p < 0.01, **** p < 0.0001. (C) Size distribution of extracellular vesicles, (D) binding affinity (KD) of extracellular vesicles to cmHsp70.1 mAb, and (E) typical exosomal surface markers such as CD9, CD81, and Hsp70 on extracellular vesicles derived from a patient with astrocytoma.

Article Snippet: The concentration of free Hsp70 in the serum samples, as measured with the R&D Systems DuoSet® Total Hsp70 ELISA, was also significantly elevated in patients with GBM (** p < 0.01) compared to the healthy i dividuals (Figure 4B), with median Hsp70 levels of 3.5 ng/mL (GBM) nd 2.6 ng/mL (healthy), respectively.

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Binding Assay, Derivative Assay

Journal: Biomedicines

Article Title: Biomarkers in Adult-Type Diffuse Gliomas: Elevated Levels of Circulating Vesicular Heat Shock Protein 70 Serve as a Biomarker in Grade 4 Glioblastoma and Increase NK Cell Frequencies in Grade 3 Glioma.

doi: 10.3390/biomedicines11123235

Figure Lengend Snippet: Figure 6. Correlation of low and high Hsp70 values in the circulation and the proportion of different NK cell subpopulations in patients with grade 3 glioma (Hsp70low n = 11; Hsp70high n = 11) and grade 4 GBM (Hsp70low n = 30; Hsp70high n = 32) compared to a healthy control cohort (n = 16). (A) CD3−/CD56+ NK cells in grade 3 and grade 4 GBM patients with high (Hsp70high) and low (Hsp70low) Hsp70 plasma levels. (B) CD56+/CD94+ NK cells in grade 3 and grade 4 GBM patients with high (Hsp70high) and low (Hsp70low) Hsp70 plasma levels. (C) CD56+/CD69+ NK cells in grade 3 and grade 4 GBM patients with high (Hsp70high) and low (Hsp70low) Hsp70 plasma levels. Statistically significant differences * p < 0.05, ** p < 0.01.

Article Snippet: The concentration of free Hsp70 in the serum samples, as measured with the R&D Systems DuoSet® Total Hsp70 ELISA, was also significantly elevated in patients with GBM (** p < 0.01) compared to the healthy i dividuals (Figure 4B), with median Hsp70 levels of 3.5 ng/mL (GBM) nd 2.6 ng/mL (healthy), respectively.

Techniques: Control, Clinical Proteomics

Journal: Neoplasia (New York, N.Y.)

Article Title: Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.

doi: 10.1016/j.neo.2023.100944

Figure Lengend Snippet: Fig. 4. Treatment-dependent release of HSP70 and treatment- and HPV-dependent release of HMGB1 of HNSCC cells. The supernatants of the tumor cells were collected 24 h after the last treatment for ELISA analyses of HSP70 (A) and HMGB1 (B). The concentrations in ng/ml per 1*106 cells are shown as stacked bars showing the mean with ±SD. A Kruskal-Wallis test with Dunn’s correction for multiple testing was calculated to compare the different treatment approaches versus the control. Non-measurable values were set to 0; *p < 0.05, **p < 0.01, ***p < 0.001, n ≥4.

Article Snippet: The assays were performed according to the manufacturer’s recommendations of the HSP70 ELISA kit (Human/Mouse/Rat Total HSP70/ HSPA1A ELISA, R&D Systems, Minneapolis, MN, USA) and the HMGB1 ELISA kit (Ibl International).

Techniques: Enzyme-linked Immunosorbent Assay, Control